Quick Answer
Indivior Pharmaceuticals, Inc. reported Long Term Debt of $290.00 million for the year ending 2025.
- Indivior Pharmaceuticals, Inc. showed a decrease of -7.9% in Long Term Debt from 2024 to 2025.
- This data is from Indivior Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2023 to 2025 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2025: $311.00 million | Q2 2025: $308.00 million | Q3 2025: $304.00 million.
- Over the full 3 years of available data (2023 to 2025), Indivior Pharmaceuticals, Inc.'s Long Term Debt has grown by 22.4%.
- Historical annual values: Fiscal year 2025: $290.00 million | Fiscal year 2024: $315.00 million | Fiscal year 2023: $237.00 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: